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The isolation and identification of bioactive metabolites from complex extracts obtained from microbial growth media is a time 
consuming, costly, and labor-intensive task. A strategy to rapidly identify secondary metabolites isolated from extracts obtained from 
the culture media of marine-derived and endophytic fungal strains is described. Identification was achieved by HPLC-UV-MS and 
1H NMR analyses in combination with data obtained from the Dictionary of Natural Products. Among the compounds identified, 
(-)-naphthoquinoneimine, citreorosein, emodin, pyrenocine A and harzianopyridone displayed moderate to potent antiviral activity. 
(-)-Naphthoquinoneimine was isolated as the enantiomer of its previously reported dextrorotatory congener, while 6,7-dihydroxy-
2,2-dimethyl-4-chromanone is herein reported for the first time as a natural product.
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INTRODUCTION
Most fungal secondary metabolites are remarkably complex 
bioactive compounds.1,2 Although they were almost dismissed in 
biodiscovery programs between the 1960’s and 1980’s, the raise 
of molecular biology tools provided compelling evidence that the 
diversity of filamentous fungi secondary metabolism is astonishingly 
higher than originally thought.3 Such metabolites are very often the 
inspiration for the development of new drug lead scaffolds and bio-
chemical tools, resulting from the fact that many of these compounds 
present unique ecological roles, particularly as antibiotics and as 
chemical mediators.
The isolation of bioactive fungal metabolites from complex and 
chemically diverse extracts is time and resources consuming, a labor-
-intensive task. The rapid identification of known natural products 
isolated from fungal extracts is essential to avoid the record and 
analysis of multiple 1D and 2D NMR experiments. This is particu-
larly true when dereplication of secondary metabolites in extracts 
of biological matrixes is unfeasible by high-resolution and high-
-throughput chromatography-spectroscopy hyphenated tools, such as 
HPLC-HRMS, HPLC-NMR and related techniques.3-7 Data obtained 
from joint UV, LRMS and 1H NMR analyses only, and sometimes 
13C NMR, can be used in querying databases such as the Dictionary 
of Natural Products (DNP), Antimarin, MarinLit, and Molecular 
Networking, as an effective combination for the rapid identification of 
known structures.8,9 The rapid identification of secondary metabolites 
enables further assessment of structures of interest, particularly of 
unprecedentedly bioactive known compounds.
The discovery of antiviral natural products is currently of seminal 
interest considering the emergence and re-emergence of viral disea-
ses such as dengue, and infections caused by chikungunya and zika 
viruses. Only fifty antiviral drugs are available to treat viral infec-
tions.10 The majority of these antivirals was introduced into clinical 
use during the last two decades, and they were discovered due to the 
urgency in developing treatments for the Human Immunodeficiency 
Virus (HIV) infection.10 Only a handful of antiviral compounds have 
been discovered from marine-derived fungi. These include sansal-
vamide A (1), produced by Fusarium sp., which exhibits antiviral 
activity against poxvirus (MCV),11 as well as halovirs A-E (2-6), 
produced by Scytalidium sp., and active against Herpes Simplex 
Virus Types 1 and 2 (HSV).12
The discovery of microbial secondary metabolites in Brazil 
increased considerably during the last 15 years. However, when con-
sidering all the microbial secondary metabolites isolated by Brazilian 
researchers between 2000 and 2013, only 28.4% were new.13 This 
probably results from the difficulty in having state-of-art tools for 
dereplication purposes, which are expensive to purchase and maintain. 
Aiming to provide a reliable procedure for the identification of known 
secondary metabolites isolated from fungal culture media, herein 
we present a practical strategy that enables the rapid identification 
of natural products by HPLC-UV-LRMS, 1H NMR and, much less 
often, by 13C NMR. Selected compounds were subsequently evaluated 
in antiviral bioassays.
EXPERIMENTAL
General experimental procedures
Solvents used for extraction and chromatography were of HPLC-
grade. Gel permeation chromatography was performed in a glass 
column (170.0 X 2.0 cm) filled with Sephadex LH-20 (Pharmacia 
Biotech). Flash chromatography was performed using a glass column 
(12.0 x 3.5 cm) filled with silica-gel 200-400 mesh (Sigma Aldrich). 
Solid-phase extraction was carried out using octadecylsilane, 
A strategy for the rapid identification of fungal metabolites and the discovery of the antiviral activity 721Vol. 39, No. 6
cyanopropyl, diol, and silica gel cartridges of different dimensions 
(Waters and Phenomenex).
HPLC-UV-MS analyses were performed using a Waters Alliance 
2695 system coupled on-line with a Waters 2996 photodiode array 
detector, followed by a Micromass ZQ2000 MS detector with an elec-
trospray interface. The photodiode array detector scanned the samples 
between lmax 200 and 400 nm. The MS detector was optimized to 
the following conditions- capillary voltage: 3.00 kV, source block 
temperature: 100 °C, desolvation temperature: 350 °C, operating 
in electrospray positive and negative modes in the detection range 
between 200 and 800 Da with total ion count extracting acquisition. 
The cone and desolvation gas flow were 50 and 350 L/h, respectively, 
and were generated by a Nitrogen Peak Scientific N110DR nitrogen 
source. Data acquisition and processing were performed using the 
Empower 2.0 software. Approximately 1 mg of each sample was 
diluted in appropriate vials containing 1 mL of methanol (MeOH). 
Analyses were performed using different C18 reversed-phase columns: 
Inertsil ODS-SP, ODS-3 or C8-4 (4.6 x 250 mm, 5 mm), with a gradi-
ent of elution of 1:1 (MeOH/MeCN) in H2O + 0.1% formic acid in 
both organic and aqueous solvents. The gradient of elution started at 
10% to 100% of the organic mixture, during 22 minutes. The flow 
rate was 1.0 mL min-1.
HPLC semi-preparative purifications were carried out using either 
a Waters 600 pump in series with a Waters 2487 dual wavelength 
absorbance detector, or a Waters 2535 quaternary gradient module 
equipped with a Waters 2489 UV-visible detector. Purifications were 
performed using analytical/semi-preparative C18 reversed-phase 
columns Inertsil ODS-SP and/or ODS-3 (4.6 x 250 mm, 5 mm), and 
C8 columns Inertsil C8-4 and/or InertSustain (4.6 x 250 mm, 5 mm 
or 14.0 x 250 mm, 5 mm).
NMR spectra were recorded on a Bruker DRX spectrometer (9.4 T, 
400 MHz for 1H), Bruker AVANCEIII spectrometer (14.1 T, 600 MHz 
for 1H) or on an Agilent Technologies 500/54 Premium Shielded 
spectrometer (11.7 T, 500 MHz for 1H). Compounds were dissolved in 
appropriate deuterated solvents containing tetramethylsilane as internal 
reference. HRMS analyses were performed using a Bruker Daltonics 
Ultra-TOF spectrometer or on a LTQ Orbitrap Thermo Scientific 
spectrometer. Optical rotation analyses were performed using either 
a Perkin Elmer 241MC polarimeter or a JASCO P2000 polarimeter.
Marine-derived fungal strains obtained from marine 
invertebrate samples
Samples of marine invertebrates were collected at Toque-Toque 
Island, off São Paulo state north coastline, in Brazil. The samples 
consisted of three marine sponges (Dragmacidon reticulatum, 
Axinellidae, Ridley & Dendy, 1886; Mycale laxissima, Mycalidae, 
Duchassaing & Michelotti, 1864; and Mycale angulosa, Mycalidae, 
Duchassaing & Michelotti, 1864) and one ascidian (Didemnum 
ligulum, Didemnidae, Monniot, 1983). Vouchers of these marine 
organisms are deposited at Museu Nacional, Universidade Federal 
do Rio de Janeiro (sponges) and at Departamento de Zoologia, Setor 
de Ciências Biológicas, Universidade Federal do Paraná (ascidian). 
The sponges were identified by Dr. Marcio R. Custódio (Instituto 
de Biociências, Universidade de São Paulo), while the ascidian was 
identified by Dra. Rosana M. Rocha (Departamento de Zoologia, 
Universidade Federal do Paraná).
Fungal strains were isolated as previously reported.14 Pure fungal 
colonies were photographed, morphologically described, subjected to 
microscopic analysis, and stored at the Grupo de Química Orgânica 
de Sistemas Biológicos, Departamento de Físico-Química, Instituto 
de Química de São Carlos. Colonies were identified by conventional 
and molecular techniques. Identification sequences for each fungal 
strain can be requested to Dra. Lara Sette (larasette@rc.unesp.br).
An endophytic fungal strain isolated from the leaves of 
Anthurium loefgrenii
Samples of leaves from ten plants were collected at Alcatrazes 
Island, Alcatrazes Archipelago (24º10’ S, 45º70’ W), off São Paulo 
state north coastline, in Brazil. Positioning, environment (surround-
ings) and occurrence data were recorded as well. All samples were 
collected in sterilized plastic bags and immediately transported to 
the Universidade de São Paulo Marine Station, CEBIMar/USP. Each 
plant sample was identified by Dr. Marco Antônio de Assis (Instituto 
de Biociências, Universidade Estadual Paulista Júlio de Mesquita 
Filho, UNESP-Rio Claro).
Leaves were cleaned from visible dust and soil with running water 
and subsequently washed according to a modified Petrini (1991)15 
protocol, as it follows: the leaves were washed in: 1) sterilized dis-
tilled water during 1 min, 2) 70% EtOH solution during 1 min, 3) 
HCl 2.5% solution during 2 min, 4) 70% EtOH solution during 1 min, 
followed by two washes with sterilized distilled water during 1 min. 
An aliquot of 100 µL from the last wash was plated on PDB culture 
media in order to confirm the surface sterilization.
For the isolation of endophytic fungi, after surface sterilization 
leaves were cut with sterilized blades into fragments of approx. 
8-12 mm, and three pieces were plated on minimum media + leaves: 
K2HPO4 (18.8 g L-1), KH2PO4 (6 g L-1), MgSO4 (5 g L-1), glycerol (10 
g L-1) and fragments of leaves (added while the media was poured). 
Figure 1. Antiviral compounds from marine-derived fungi: sansalvamide A (1) and halovirs A-E (2-6)
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Tetracycline (100 mg L-1) and streptomycin (20 mg L-1) were 
added in all media used for inoculation in order to prevent bacterial 
contamination.
Growth in Petri dishes was performed at 28 oC. After inocula-
tion, the plates were regularly examined in order to verify the growth 
of filamentous fungi. Pure fungal colonies obtained by successive 
purification steps were transferred to plates containing MEA (Malt 
Extract Agar, composition: malt extract 20 g, glucose 20 g, peptone 
1 g, agar 20 g) medium without antibiotics.
Crude extracts from culture media
Pure marine-derived fungal strains were first grown in Petri dishes 
using either 2% malt (malt extract 20 g, artificial sea water 1 L, agar 
15 g) or 3% malt (malt extract 30 g, mycological peptone 3 g, artificial 
sea water 1 L, agar 15 g) culture media. Composition of artificial 
sea water (ASW) was 1.36 g of CaCl2·H2O, 9.68 g of MgCl2·2H2O, 
0.61 g of KCl, 30 g of NaCl, 140 mg of NaH2PO4, 3.47 g of Na2SO4, 
170 mg of NaHCO3, 100 mg of KBr, 40 mg of SrCl2·6H2O, and 30 
mg of HBO3 in 1 L of distilled water. Strains DRG1M2, DLM212, 
DLM218, F56, and F254 were maintained in 2% malt, while strains 
DLM33 and DLM38 were maintained in 3% malt. The endophytic 
fungal strain P2AF2F3 was maintained in 2% malt without ASW. 
After growth, 2 mm of mycelia surface samples were obtained using 
sterilized Pasteur pipettes, and inoculated in 250 mL of culture media 
broth of identical formulation to that used for the strains growth on 
Petri dishes (except for the agar). The strains were grown in static 
mode for 21 days at room temperature. After growth, an equal volume 
of ethyl acetate (EtOAc) was added to the cultures, and the mixture 
of mycelia, culture media, and EtOAc was filtered through a celite 
bed. The organic phase was separated by liquid-liquid extraction, and 
subsequently dried under vacuum.
Rapid identification procedure for pure compounds
Pure compounds were analyzed by HPLC-UV-MS. Data from MS 
and UV spectra obtained for each compound were used as query for 
a search on Dictionary of Natural Products. If too many outcomes 
were returned, another query using organism taxonomic information 
was made to restrict the search. Since all compounds were isolated 
from fungal culture media, queries were also performed using the 
keywords “fungal” or “fungi” or “fungus”. If no unambiguous 
identification was possible at this step, the 1H NMR spectrum of the 
isolated compound was recorded. Typical 1H signals were used for 
identification purposes, such as those of singlet or doublet methyl 
groups, vinylic or benzene hydrogens. In the few instances when 
organism taxonomical information, UV, LRMS and 1H NMR data did 
not provide enough information for the unambiguous identification 
of the pure compound, the 13C NMR spectrum was also recorded and 
analyzed. No further 2D NMR or HRMS analysis were necessary to 
identify pure known compounds.
Isolation and identification of fungal secondary metabolites
Aspergillus sydowii DRG1M2, isolated from the sponge 
Dragmacidon reticulatum, was inoculated in 8 L of 2% malt extract 
medium (in thirty-two 500 mL Schott flasks containing 250 mL of 
culture medium each). After growth, 250 mL of EtOAc were added 
to each Schott flask. This mixture was filtered and the organic phase 
was separated by liquid-liquid extraction. After evaporation, the 
EtOAc extract (2 g) was resuspended in MeOH and deffated with 
hexane. The MeOH extract (1.5 g) was subjected to a gel permeation 
chromatography using Sephadex LH-20 gel and MeOH as mobile 
phase. Six fractions were obtained after analysis by thin layer chro-
matography (eluent: 9:1 CH2Cl2/MeOH; observed under UV light at 
lmax 254 nm). Fraction DRG1M2-MC (284.3 mg) presented peaks 
with UV absorptions at 210-220, 240-250, and 300-310 nm, as well 
as compounds with molecular weights in the range between 240 and 
250 Da by HPLC-UV-MS analysis. This fraction was subjected to 
a solid-phase extraction on a silica-gel cartridge (5 g) eluted with 
8:2, 7:3, 6:4, 1:1 [1:1 (Hex/CH2Cl2)]/EtOAc], 8:2, 7:3, 6:4, 1:1 
CH2Cl2/AcOEt, 9:1, 1:1 CH2Cl2/MeOH and 100% MeOH. From 
this separation three fraction were obtained. HPLC purification of 
fraction DRG1M2-MC2 (95.4 mg, column: Inertsil ODS-SP; eluent: 
20:20:60 MeOH/MeCN/H2O + 0.1% formic acid; flow rate of 1.0 mL/
min; detection at l = 254 and 340 nm) led to the isolation of 6.8 mg 
of sydowic acid (7).16 The compound was identified by analysis of 
spectroscopic data and comparison with literature data. The absolute 
configuration of (7) was established by comparison of its [α]D23.3 –4 
(c 0.1, MeOH) with literature values.
Aspergillus sp. DLM38, isolated from the ascidian Didemnum 
ligulum, was grown in 4 L of 3% malt extract medium (divided in 
Shott flasks as described above). After liquid-liquid extraction with 
EtOAc and evaporation of the organic phase, the EtOAc extract 
(2.8 g) was subjected to a solid-phase extraction on a cyanopropyl-
-bonded silica-gel cartridge (10 g) eluted with 9:1, 8:2, 7:3, 6:4, 1:1 
[1:1 (Hex/CH2Cl2)]/[1:1 (EtOAc/MeOH)] and 100% MeOH. Four 
fractions were obtained after analysis by thin layer chromatography 
(eluent: 9:1 CH2Cl2/MeOH; observed under UV light at lmax 254 nm). 
Analysis by HPLC-UV-MS indicated that fractions DLM38-A (1.4 
g) and DLM38-CE (161.7 mg) presented peaks with UV absorptions 
at 210-230, 250-290 and 320-330 nm, as well as a compounds with 
molecular weights in the range between 250 and 600 Da. Fraction 
DLM38-A was subjected to a solid-phase extraction on a silica-
-gel cartridge (5 g) eluted with 9:1, 8:2, 7:3, 6:4, 1:1 [75:25 (Hex/
CH2Cl2)]/[90:10 (EtOAc/MeOH)], 100% [90:10 (EtOAc/MeOH)] 
and 100% MeOH. After analysis by thin layer chromatography 
(eluent: 9:1 CH2Cl2/MeOH; observed under UV light at lmax 254 
nm), this separation yielded 520.0 mg of DLM38-A1 and 45.5 mg of 
DLM38-A5. The fraction DLM38-A1 was subjected to a separation 
by flash chromatography using a glass column filled with silica-gel 
(200-400 mesh) and eluted with 90:10, 85:15, 80:20, 75:25, 70:30, 
65:35, 60:40, 55:45, 50:50 [1:1 (Hex/CH2Cl2)]/[1:1:1 (EtOAc/
MeOH/MeCN)], 100% [1:1:1 (EtOAc/MeOH/MeCN)], 1:1 MeOH/
MeCN, and 100% MeOH. This separation yielded four fractions, 
of which DLM38-A1B (209.4 mg) and DLM38-A1C (59.5 mg) 
were selected for HPLC purification. The fraction DLM38-A1B 
was purified by HPLC using a C8 reversed-phase column Inertsil 
C8-4 with an isocratic elution (60:40 MeOH/H2O), at a flow rate of 
7.5 mL min-1, and detection at lmax 254 nm. This separation led to 
the isolation of 6.5 mg of (-)-naphthoquinoneimine (8), identified by 
analysis of spectroscopic data and comparison with literature data.17 
The absolute configuration of (8) was established by comparison 
of its optical rotation value [α]D25 –8 (c 3.1, MeOH) with literature 
data.17 Purification of the fraction DLM38-A1B6 (51.4 mg, column: 
Inertsil Ph; eluent: 1:1 [1:1 (MeCN/i-PrOH)/H2O], flow rate of 1.0 
mL/min; detection at lmax 275 nm) led to the isolation of 1.3 mg of 
aurosperone A (9).18,19 Purification of the fraction DLM38-A1C by 
HPLC (column: Inertsil C8-4; eluent: 60:40 MeOH/H2O, flow rate 
of 7.5 mL/min, detection at lmax 310 nm) led to the isolation of 8.1 
mg of pyranonigrin C (10)20 and 9.5 mg of aurosperone C (11).19 
Purification of the fraction DLM38-A5 by HPLC (column: Inertsil 
ODS-3; isocratic elution: 70:30 [1:1 (MeOH/MeCN)/H2O] during 
35 minutes, followed by a gradient elution [1:1 (MeOH/MeCN)]/
H2O from 50 to 60% [1:1 (MeOH/MeCN)] in 25 minutes, then an 
isocratic elution of 100% 1:1 (MeOH/MeCN) during 5 minutes; flow 
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rate: 1.0 mL/min; detection at lmax 280 nm) led to the isolation of 1.9 
mg of pyrophen (12).19,21 Purification of the fraction DLM38-CE by 
HPLC (column: Inertsil ODS-3; gradient elution with 1:1 (MeOH/
MeCN)/H2O from 30 to 42% [1:1 (MeOH/MeCN) during 20 minutes, 
then isocratic elution of 100% [1:1 (MeOH/MeCN)] during 6 minutes; 
flow rate: 1.0 mL/min; detection at l = 280 nm) led to the isolation 
of 2.0 mg of leucomelone (13)22 and of 2.1 mg of atromentin (14).23
A second investigation of the strain Aspergillus sp. DLM38 was 
performed with 10 L of 3% malt extract medium. After liquid-liquid 
extraction with EtOAc and evaporation of the organic phase, the 
EtOAc extract (4.8 g) was subjected to a solid-phase extraction on a 
silica-gel cartridge (10 g) eluted with 8:2:0, 6:4:0, 0:1:0, 0:1:1 CH2Cl2/
EtOAc/MeOH, and four fractions were obtained. Fraction DLM38-F2 
(458.2 mg) was subjected to a separation using a C18 reversed-phase 
silica-gel cartridge (10 g) eluted with 1:3, 1:1, 3:1, 0:1 H2O/MeOH. 
After HPLC-UV-MS analysis, these fractions were pooled in two 
fractions DLM38-F2A (78.6 mg) and DLM38-F2B (310.1 mg). 
DLM38-F2A was separated by HPLC using a C8 reversed-phase 
column InertSustain C8 (14.0 x 250 mm, 5 mm) and isocratic elution 
of 2:3 MeOH/H2O during 28 minutes, flow rate of 4.0 mL/min, and 
detection at lmax 254 and 280 nm, to give 1.8 mg of (10) and 8.7 mg 
of pyranonigin B (15)20. Fraction DLM38-F2B presented peaks with 
UV absorptions around 230, 280 and 330 nm, as well as compounds 
with molecular weights in the range between 575 and 607 Da, cor-
responding to aurosperones derivatives previously isolated, so this 
fraction was ignored.
Penicillium glabrum DLM218, isolated from the ascidian 
Didemnum ligulum, was grown in 8 L of 2% malt extract medium (in 
Shott flasks, as described above). After liquid-liquid extraction with 
EtOAc and evaporation of the organic phase, the EtOAc extract (2.9 
g) was subjected to a solid-phase extraction on a C18 reversed-phase 
silica-gel cartridge (10 g) eluted with 15:85, 30:70, 50:50, 70:30, 
85:15 MeOH/H2O and 100% MeOH. Analysis by HPLC-UV-MS 
of the fractions DLM218-ABC (1.19 g) and DLM218-E (470.7 mg) 
showed peaks with UV absorptions at lmax 220-230, 250-270, 280-300 
and 385 nm, and compounds with molecular weights in the range 
between 270 and 390 Da. Fraction DLM218-ABC was separated by 
HPLC using a C8 reversed-phase column Inertsil C8-4 and gradient 
elution from 20% MeOH/H2O to 100% MeOH during 55 minutes, 
flow rate of 8.0 mL/min, and detection at lmax 280 and 300 nm. 
HPLC-UV-MS analysis of the fraction DLM218-ABC7 (65.1 mg) 
indicated a major peak with lmax 283, 307, and 383 nm in the UV 
spectrum, a peak with m/z 381.2 in the mass spectrum corresponding 
to the [M+H]+ ion, and a peak with m/z 379.3 corresponding to the 
[M-H]- ion of compound (15). HPLC purification (column: Inertsil 
C8-4; isocratic elution: 64:36 MeOH/H2O; flow rate of 7.0 mL/min; 
detection at lmax 280 and 300 nm) of the major compound led to the 
isolation of 5.7 mg of penicitrinone A (16).24 Fraction DLM218-E 
(88.9 mg) was separated by HPLC using a C8 reversed-phase column 
Inertsil C8-4 (isocratic elution with 58:42 MeOH/H2O; flow rate of 7.0 
mL/min; detection at lmax 275 and 310 nm). HPLC-UV-MS analysis of 
the fraction DLM218-E4 (88.9 mg) indicated a major peak with lmax 
235, 263, 295 and 384 nm in the UV spectrum, a peak with m/z 299.3 
in the mass spectrum corresponding to the [M+H]- ion, and a peak 
with m/z 323.1 corresponding to the [M+Na]+ ion of compound (17). 
HPLC purification of (17) (column: Inertsil C8-4; isocratic elution: 
59:41 MeOH/H2O, flow rate of 7.0 mL/min, detection at lmax 254 
and 280 nm) led to the isolation of 5.2 mg of pinselin (17).25 HPLC-
UV-MS analysis of the fraction DLM218-E6 (217.4 mg) indicated 
two major peaks with lmax 283, 307, 383, and 221, 266, 287 nm in 
the UV spectrum, with m/z 381.1 and 271.2 in the mass spectrum, 
corresponding to the [M+H]+ ions of (15) and (18), respectively. 
HPLC purification of (15) and (18) (column: Inertsil C8-4; isocratic 
elution: 49:51 MeCN/H2O; flow rate of 7.0 mL min-1; detection at 
lmax 254 and 280 nm) led to the isolation of 13.3 mg of (15) and 
9.4 mg of emodin (18).26
Penicillium citrinum DLM212, isolated from the ascidian 
Didemnum ligulum, was grown in 8 L of 2% malt extract medium (in 
Shott flasks as described above). After liquid-liquid extraction with 
EtOAc and evaporation of the organic phase, the EtOAc extract (2 
g) was resuspended in MeOH and deffated with hexane. The MeOH 
fraction (1.5 g) was subjected to a gel permeation chromatography 
using a glass column filled with Sephadex LH-20 gel and MeOH as 
mobile phase. Six fractions were obtained after analysis by thin layer 
chromatography (eluent: 9:1 CH2Cl2/MeOH; observed under UV light 
at lmax 254 nm), of which DLM212-MB (122.4 mg), DLM212-MC 
(551.5 mg) and DLM212-ME (66.8 mg) presented peaks with UV 
absorptions at lmax 210-230, 250-290, and 315 nm, in the mass range 
between 250 and 300 Da by HPLC-UV-MS analysis. The fraction 
DLM212-MB was separated by HPLC using a C18 reversed-phase 
column Inertsil ODS-SP (isocratic elution with 35:35:30 MeOH/
MeCN/H2O + 0.1% formic acid; flow rate of 1.0 mL/min; detection 
at lmax 270 and 340 nm). HPLC purification of the fraction DLM212-
MB2 (35.0 mg) (column: Inertsil ODS-SP; isocratic elution: 25:25:50 
MeOH/MeCN/H2O + 0.1% formic acid; flow rate of 1.0 mL/min; 
detection at lmax 270 and 340 nm) led to the isolation of 1.0 mg 
of quinolactacin B (19).27 HPLC-UV-MS analysis of the fraction 
DLM212-MB4 (9.0 mg) indicated a major peak with lmax 224 and 
283 nm in the UV spectrum, and a peak with m/z 298.3 in the mass 
spectrum, corresponding to the [M+H]+ ion of (20). Purification of 
(20) by HPLC (column: Inertsil ODS-SP; isocratic elution: 35:35:30 
MeOH/MeCN/H2O + 0.1% formic acid; flow rate of 1.0 mL/min; 
detection at lmax 254 and 270 nm) led to the isolation of 2.3 mg 
of penicillenol A (20).28 Purification of the fraction DLM212-ME 
(66.8 mg) by HPLC (column: Inertsil ODS-SP; isocratic elution: 
35:35:30 MeOH/MeCN/H2O + 0.1% formic acid; flow rate of 1.0 
mL/min; detection at lmax 270 and 340 nm) led to the isolation of 14.7 
mg of citreorosein (21)29 and 15.4 mg of (18). Fraction DLM212-MC 
was subjected to a solid-phase extraction on a cyanopropyl-bonded 
silica-gel cartridge (10 g) eluted with 8:2, 7:3, 6:4, 1:1 CH2Cl2/EtOAc, 
100% EtOAc, 1:1 EtOAc/MeOH and 100% MeOH. HPLC purifica-
tion of DLM212-MC2 (83.7 mg, column: Inertsil ODS-SP; isocratic 
elution: 15:15:70 MeOH/MeCN/H2O + 0.1% formic acid; flow rate 
of 1.0 mL/min; detection at lmax 254 and 280 nm) yielded 2.0 mg of 
DLM212-MC2E. HPLC-UV-MS analysis of this fraction indicated 
a major peak with lmax 218, 250 and 316 nm in the UV spectrum, 
and a peak with m/z 287.0 in the mass spectrum, corresponding to 
the [M+H]+ ion of the quinolactacin C (22).27
Roussoella sp. DLM33, isolated from the ascidian Didemnum 
ligulum, was grown in 10 L of 3% malt extract medium (as described 
above). After liquid-liquid extraction of the growth medium with 
EtOAc and evaporation of the organic phase, the EtOAc extract 
(1.78 g) was separated by gel permeation chromatography using 
Sephadex LH-20 gel and MeOH as mobile phase. After analysis by 
thin layer chromatography (eluent: 9:1 CH2Cl2/MeOH; observed 
under UV light at lmax 254 nm) four fractions were obtained, of which 
DLM33-A7 (141.5 mg) gave a precipitate (DLM33-A7-ppt = 16.9 
mg). Chromatographic separation of this solid on a silica-gel cartridge 
yielded 9.5 mg of 5-methylmellein (23).30 The absolute configura-
tion of (23) was established by comparison of its [α]D25 –81 (c 1.24, 
MeOH) with literature data.30 Fraction DLM33-A7 was subjected to 
a chromatographic separation on a silica gel cartridge (5 g) eluted 
with 9:1 [1:9 (Hex:CH2Cl2)]/[95:5 (EtOAc:MeOH)]. This separa-
tion yielded 42.1 mg of DLM33-A7A19. Fraction DLM33-A7A19 
was separated by HPLC using a C18 reversed-phase column Inertsil 
ODS-SP (gradient of elution from 10% MeOH/H2O to 50% MeOH 
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during 25 minutes; flow rate of 1.0 mL/min; detection at lmax 254 
and 280 nm). HPLC purification of the fraction DLM33-A7A19M 
(21.2 mg) (column: Inertsil C8-4; isocratic elution: 46:54 MeOH/
H2O; flow rate of 1.0 mL/min; detection at lmax 254 and 280 nm) 
led to the isolation of 1.0 mg of 5,7-dichloro-3-methyl-6-methoxy-
8-hydroxy-3,4-dihydroisocoumarin (24).31
Cochliobolus sp. F56, isolated from the sponge Mycale laxis-
sima, was grown in 2 L of 2% malt extract medium (in ten 500 mL 
Schott flasks containing 200 mL of medium each). After liquid-
liquid extraction of the growth medium with EtOAc and evaporation 
of the organic phase, the EtOAc extract (407.2 mg) was subjected to 
a separation by gel permeation chromatography using Sephadex LH-
20 gel and MeOH as mobile phase. Five fractions were obtained after 
analysis by thin layer chromatography (eluent: 9:1 CH2Cl2/MeOH; 
observed under UV light at lmax 254 nm), of which F56-A2 (141.5 
mg) and F56-A4 (17.4 mg) were chosen for purification procedures. 
The fraction F56-A2 was subjected to a solid-phase extraction on 
a diol-bonded silica-gel cartridge (5 g) eluted with 6:4 [1:1 (Hex/
CH2Cl2)]/EtOAc, 100% EtOAc, 1:1 EtOAc /MeOH and 100% 
MeOH. HPLC-UV-MS analysis of the fraction F56-A2(4) (32.9 
mg) indicated a major peak with lmax 261 nm in the UV spectrum, 
and a peak with m/z 287.3 in the mass spectrum, corresponding to 
the [M+H]+ ion of 25. HPLC purification of (25) (column: Inertsil 
ODS-SP; isocratic elution: 21:21:58 MeOH/MeCN/H2O + 0.1% 
formic acid; flow rate of 1.0 mL/min; detection at lmax 230 and 
254 nm) led to the isolation of 4.0 mg of (+)-abscisic acid (25).32 
The absolute configuration of 25 was established by comparison of 
its [α]D25 +87 (c 2.0, MeOH) with literature data. Fraction F56-A4 
was separated by HPLC using a reversed-phase C18 column Inertsil 
ODS-SP (isocratic elution with 24:24:52 MeOH/MeCN/H2O + 0.1% 
formic acid; flow rate of 1.0 mL/min; detection at l = 230 and 320 
nm). This separation led to the isolation of 2.2 mg of 4-hydroxy-
3-(3-methylbut-2-enyl)benzoic acid (26)33 and of 1.0 mg of anofinic 
acid (27).33 HPLC-UV-MS analysis of fraction F56-A4(2) indicated 
a major peak with lmax 240, 279 and 347 nm in the UV spectrum, 
and a peak with m/z 209.07 in the mass spectrum, corresponding 
to the [M+H]+ ion of (28). Purification by HPLC (column: Inertsil 
ODS-SP; isocratic elution with 20:20:60 MeOH/MeCN/H2O + 
0.1% formic acid; flow rate of 1.0 mL/min; detection at lmax 230 
and 320 nm) of the major compound led to the isolation of 0.8 mg 
of 2,3-dihydro-6,7-dihydroxy-2,2-dimethylchromen-4-one (28).
Trichoderma sp. F254, isolated from the sponge Mycale laxissi-
ma, was grown in 2 L of 2% malt extract medium (as for Cochliobolus 
sp. F56). After liquid-liquid extraction with EtOAc and evaporation 
of the organic phase, the EtOAc extract (241.6 mg) was separated 
by gel permeation chromatography using Sephadex LH-20 gel and 
MeOH as mobile phase. After analysis by thin layer chromatography 
(eluent: 9:1 CH2Cl2/MeOH; observed under UV light at lmax 254 nm) 
six fractions were obtained, of which F254-E (59.9 mg) was purified 
by HPLC (column: Inertsil ODS-SP; gradient elution: [1:1 (MeOH/
MeCN)]/ H2O + 0.1% formic acid from 20 to 80% [1:1 (MeOH/
MeCN)] during 30 minutes, then from 80 to 100% 1:1 (MeOH/
MeCN) during 1 minute and isocratic elution at 100% 1:1 (MeOH/
MeCN) during 4 minutes; flow rate of 1.0 mL/min; detection at lmax 
254 and 280 nm). This procedure led to the isolation of 5.9 mg of 
harzianopyridone (29).34
Penicillium paxilli Ma(G)K, isolated from the sponge Mycale 
angulosa, was grown 2 L of 2% malt medium (as for Cochliobolus 
sp. F56). The culture was incubated in a rotary shaker (100 rpm) at 
25 °C for seven days. At the end of the growth period, 200 mL of 
EtOAc were added to each Schott flask. The mixture was shaken at 
100 rpm for 24 h at 25 °C, filtered through a celite bed and the organic 
phase was separated by liquid-liquid extraction. After evaporation, the 
EtOAc extract (400 mg) was subjected to a solid-phase extraction on a 
cyanopropyl-bonded silica-gel cartridge (2 g), eluted with 100% CH2Cl2 
(fraction Ma(G)K-A, 130.0 mg), 100% EtOAc (fraction Ma(G)K-B, 
68.2 mg), and finally eluted with 100% MeOH (fraction Ma(G)K-C, 
155.0 mg). Fraction Ma(G)K-A was separated by HPLC using a C18 
reversed-phase column Inertsil ODS-3 (4.6 × 250 mm; 5 µm) (isocratic 
elution with 1:1 MeOH/MeCN in H2O + 0.1% formic acid), flow rate 
of 1.0 mL/min, and detection at lmax 254 nm. This separation yielded 
42.7 mg of pyrenocine A (30)14,35 and 6.0 mg of pyrenocine B (31).14,35
The yet unidentified fungal strain P2AF2F3, isolated from the 
plant Anthurium loefgrenii, was inoculated in 10 L of 2% malt 
extract medium (in thirty-two 500 mL Schott flasks containing 250 
mL of media each). After liquid-liquid extraction with EtOAc and 
evaporation of the organic phase, the EtOAc extract (900 mg) was 
resuspended in MeOH and deffated with hexane. The MeOH extract 
was subjected to a gel permeation chromatography using Sephadex 
LH-20 gel and MeOH as mobile phase. Five fractions were obtained. 
The fraction P2AF2F3-3 (530 mg) was subjected to a solid-phase 
extraction on a diol cartridge (10 g) eluted with 9:1, 8:2, 7:3, 6:4 [(1:9 
Hex/CH2Cl2)/(1:9 EtOAc/MeOH)] and 100% (1:9 EtOAc/MeOH). 
From this separation five others fractions were obtained. Fraction 
P2AF2F3-3A (200 mg) was subjected to a solid-phase extraction 
on a C18 cartridge (10 g) eluted with 3:7 and 6:4 MeOH/H2O, then 
100% MeOH. Fraction P2AF2F3-3A2 (154 mg) presented peaks 
with UV absorptions at 220-240 nm, in the mass range between 240 
and 280 Da by HPLC-UV-MS analysis. HPLC purification of frac-
tion P2AF2F3-3A2 (column: IntertSustain C8; eluent: 1:1:3 MeOH/
MeCN/H2O; flow rate of 1.0 mL/min; detection at lmax 255 and 215 
nm) led to the isolation of 3.2 mg of conocenol B (32).36
Spectroscopic data of pure compounds isolated from fungal 
strains
Sydowic acid (7): yellow oil. UV (lmax nm): 212, 244, 299. 1H 
NMR (400 MHz, TMS, DMSO-d6,): d (ppm); 0.97 (3H, s, H3-12), 
0.98 (3H, s, H3-13), 1.06 (1H, m, H-9A), 1.25 (2H, m, H2-10), 1.30 
(1H, m, H-9B),1.50 (3H, s, H3-14), 1.66 (1H, m, H-8A), 1.92 (1H, m, 
H-8B), 5.55 (1H, s, OH-1), 7.28 (1H, d, J= 1.7 Hz, H-2), 7.33 (1H, 
dd, J=8.0, 1.7 Hz, H-4), 7.39 (1H, d, J= 8.0 Hz, H-5), 9.98 (1H s, 
OH-15).13C NMR (100 MHz, TMS, DMSO-d6,): d (ppm); 18.7 (C-9), 
28.4 (C-14), 29.4 (C-13), 29.5 (C-12), 42.1 (C-8), 44.2 (C-10), 68.9 
(C-11), 75.0 (C-7), 116.8 (C-2), 119.9 (C-5), 127.1 (C-4), 130.3 (C-3), 
138.1 (C-6), 154.8 (C-1), 167.4 (C-15). ESI+-MS: m/z 247 [M-H2O]+ 
(calcd for C15H19O3, 247.13342 ). [α]D23.3 –4 (c 0.1, MeOH).
(-)-Naphthoquinoneimine (8): red amorphous solid. UV (lmax nm): 
207, 270, 334. 1H NMR (400 MHz, TMS, MeCN-d3,): d (ppm); 3.22 
(1H, dd, J=13.9, 8.2 Hz, H-8A’), 3.31 (1H, dd, J=13.9, 6.0 Hz, H-8B’), 
3.77 (3H, s, H3-9’), 4.51 (1H, ddd, J=8.2, 8.0, 6.0 Hz, H-7’), 5.46 (1H, 
d, J=2.3 Hz, H-5’), 5.51 (1H, s, H-3), 5.99 (1H, d, J=2.3 Hz, H-3’), 
6.39 (1H, d, J=8.0 Hz, NH-10’), 6.51 (1H, d, J=2.4 Hz, H-8), 6.96 
(1H, d, J=2.4 Hz, H-6), 7.28 (5H, m, H-2’, H-3’, H-4’, H-5’, H-6’), 
12.91 (1H, s, 0H-5). 13C NMR (100 MHz, TMS, MeCN-d3,): d (ppm); 
38.3 (C-8’), 55.7 (C-7’), 56.2 (C-9’), 88.3 (C-5’), 100.4 (C-3’), 101.2 
(C-3), 107.9 (C-4a), 108.9 (C-6), 117.3 (C-8), 127.1 (C-4’’), 128.6 
(C-3’’, C-5’’), 129.2 (C-2’’, C-6’’), 132.2 (C-8a), 136.3 (C-1’’), 147.5 
(C-2), 161.0 (C-2’), 163.2 (C-5), 163.3 (C-7), 163.4 (C-6’), 170.8 
(C-4’), 180.7 (C-1), 188.4 (C-4). ESI+-HRMS: m/z 434.1235 [M+H]+ 
(calcd for C24H20NO7, 434.1). [α]D25 –8 (c 3.1, MeOH).
Aurosperone A (9): yellow solid. UV (lmax nm): 228, 258, 277.1H 
NMR see refs. 18 and 19. ESI+-MS: m/z 571.1 [M+H]+ (calcd for 
C32H27O10, 571.2).
Pyranonigrin C (10): amorphous solid. UV (lmax nm): 231, 
290, 329. 1H NMR see ref. 20. ESI+-MS: m/z 254.4 [M+H]+ (calcd 
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for C11H12NO6, 254.1), ESI+-MS: m/z 529.2 [2M+Na]+ (calcd for 
C22H22N2NaO12, 529.1).
Aurosperone C (11): amorphous solid. UV (lmax nm): 233, 282, 
334. 1H NMR (400 MHz, TMS, MeCN-d3,): d (ppm); 1.44 (3H, s, 
H3-11’), 1.68 (3H, s, H3-2), 2.83 (2H, d, J=16.5 Hz, H2-3’), 3.09 
(2H, d, J=16.5 Hz, H2-3), 3.49 (3H, s, H3-12), 3.59 (3H, s, H3-13’), 
3.92 (3H, s, H3-12’), 6.13 (1H, s, H-7’), 6.40 (1H, s, H-9’), 6.59 (1H, 
s, H-9), 6.92 (1H, s, H-10). ESI+-MS: m/z 593.1 [M+H]+ (calcd for 
C31 H29O12, 593.2).
Pyrophen (12): yellow crystal. UV (lmax nm): 265. 1H NMR (400 
MHz, TMS, DMSO-d6): d (ppm); 1.78 (3H, s, H3-15), 2.89 (1H, dd, 
J=13.7, 8.2 Hz, H-7A), 3.02 (1H, dd, J=13.7, 8.2 Hz, H-7B), 3.78 (3H, 
s, H3-16), 4.76 (1H, q, J=8.2 Hz, H-6), 5.57 (1H, d, J=2.1 Hz, H-2), 
6.05 (1H, d, J=2.1 Hz, H-4), 7.19 (2H, m, H-9, H-13), 7.21 (1H, m, 
H-11), 7.27 (2H, m, H-10, H-12 ), 8.46 (1H, d, J=8.2 Hz, NH-6). 13C 
NMR (100 MHz, TMS, DMSO-d6,): d (ppm); 22.8 (C-15), 39.0 (C-7), 
52.5 (C-6), 56.9 (C-16), 88.4 (C-2), 99.8 (C-4), 127.2 (C-11), 128.7 
(C-10, C-12), 129.4 (C-9, C-13), 137.0 (C-8), 163.8 (C-5), 164.2 
(C-1), 169.0 (C-14), 170.0 (C-3). ESI--MS: m/z 323.2 [M+Cl]- (calcd 
for C16H17ClNO4, 322.1). [α]D25 0 (c 0.7, MeOH).
Leucomelone (13): amorphous solid. UV (lmax nm): 265. 1H 
NMR (400 MHz, TMS, DMSO-d6,): d (ppm); 6.67 (1H, d, J=8.2 
Hz, H-5’), 6.70 (2H, d, J=8.4 Hz, H-3’’, H-5’’), 6.75 (1H, dd, J=8.2, 
2.1 Hz, H-6’), 6.90 (1H, d, J=2.1 Hz, H-2’), 7.29 (2H, d, J=8.4 Hz, 
H-2’’, H-6’’). ESI--MS: m/z 339.2 [M-H]- (calcd for C18H11O7, 339.1).
Atromentin (14): amorphous solid. UV (lmax nm): 266. 1H NMR 
(400 MHz, TMS, DMSO-d6,): d (ppm); 6.74 (1H, d, J=8.6 Hz, H-3’), 
7.24 (1H, d, J=8.6 Hz, H-2’). ESI--MS: m/z 323.2 [M-H]- (calcd for 
C18H11O6, 323.1 ).
Pyranonigrin B (15): amorphous solid. UV (lmax nm): 233, 
291, 371. 1H NMR see ref. 20. ESI+-MS: m/z 254.4 [M+H]+ (calcd 
for C11H12NO6, 254.1), ESI+-MS: m/z 237.1 [M-H2O]+ (calcd for 
C11H11NO5, 237.0).
Penicitrinone A (16): amorphous solid. UV (lmax nm): 283, 307, 
383. 1H NMR (400 MHz, TMS, DMSO-d6): d (ppm); 1.28 (3H, d, 
J=7.0 Hz, H3-10), 1.30 (3H, d, J=6.8 Hz, H3-9’), 1.34 (6H, d, J=6.6 
Hz, H3-9, H3-8’), 2.17 (3H, s, H3-10’), 2.24 (3H, s, H3-11), 3.39 
(1H, dq, J=7.0, 3.5 Hz, H-4), 3.51 (1H, q, J=6.6 Hz, H-3), 4.73 (dq, 
6.8, 3.5 Hz, H-3’), 5.41 (1H, q, J=6.6 Hz, H-2’), 6.92 (1H, s, H-7). 
ESI+-MS: m/z 381.2 [M+H]+ (calcd for C23H25O5, 381.2), ESI--MS: 
m/z 379.3 [M-H]- (calcd for C23H23O5, 379.2).
Pinselin (17): amorphous solid. UV (lmax nm): 235, 263, 295, 
384. 1H NMR (400 MHz, TMS, DMSO-d6): d (ppm); 2.40 (3H, s, 
H3-11), 3.85 (3H, s, H3-13), 6.66 (1H, s, H-2), 6.90 (1H, s, H-4), 
7.49 (1H, d, J=8.0 Hz, H-6), 7.61 (1H, d, J=8.0 Hz, H-5), 8.40 (1H, 
s, OH-7), 12.19 (1H, s, OH-1).13C NMR (100 MHz, TMS, DMSO-d6): 
d (ppm); 22.5 (C-11), 52.7 (C-13), 106.4 (C-3) 107.8 (C-4) 111.2 
(C-1), 117.4 (C-4a), 117.6 (C-9a), 120.5 (C-2), 125.8 (C-10a), 149.1 
(C-8a), 149.7 (C-8), 155.9 (C-7), 160.8 (C-5), 167.3 (C-12), 180.7 
(C-9). ESI+-MS: m/z 323.1 [M+Na]+ (calcd for C16H12NaO6, 323.1), 
ESI--MS: m/z 299.2 [M+H]- (calcd for C16H11O6, 299.1).
Emodin (18): yellow amorphous solid. UV (lmax nm): 221, 266, 287. 
1H NMR (400 MHz, TMS, DMSO-d6): d (ppm); 2.38 (3H, s, H3-11), 
6.56 (1H, d, J=4.0 Hz, H-6), 7.08 (1H, d, J=4.0 Hz, H-8), 7.12 (1H, 
br s, H-2), 7.44 (1H, br s, H-4), 11.34 (1H, s, OH-1), 11.96 (1H, s, 
OH-7), 12.04 (1H, s, OH-5). 13C NMR (100 MHz, TMS, DMSO-d6,): 
d (ppm); 21.9 (C-11), 108.3 (C-8), 109.1 (C-10a), 109.3 (C-4a), 113.8 
(C-6), 120.9 (C-4), 124.5 (C-2), 133.2 (C-9a), 135.5 (C-8a), 148.7 (C-
3), 161.8 (C-1), 164.9 (C-7), 166.0 (C-5), 181.7 (C-9), 190.1 (C-10). 
ESI+-MS: m/z 271.2 [M+H]+ (calcd for C15H11O5, 271.1 ).
Quinolactacin B (19): white powder. UV (lmax nm): 213, 256, 
315. 1H NMR see ref. 27. ESI+-MS: m/z 257.2 [M+H]+ (calcd for 
C15H17N2O2, 257.1).
Penicillenol A (20): yellow oil. UV (lmax nm): 224, 283. 1H NMR 
(400 MHz, TMS, DMSO-d6): d (ppm); 0.86 (3H, t, J=6.4 Hz, H3-15), 
1.14 (3H, d, J=6.6 Hz, H3-7), 1.18 (3H, d, J=6.6 Hz, H3-16), 1.45 
(1H, m, H-10B), 1.25 (8H, br s, H2-11, H2-12, H2-13, H2-14), 1.69 
(1H, m, H-10A), 2.99 (3H, s, H3-17), 3.56 (1H, m, H-9), 3.81 (1H, 
d, J=4.8 Hz, H-5), 4.19 (1H, m, H-6). 13C NMR (100 MHz, TMS, 
DMSO-d6): d (ppm); 14.0 (C-15), 17.2 (C-16), 17.8 (C-7), 22.6 (C-
13), 27.1 (C-11), 27.2 (C-17), 29.2 (C-12), 31.7 (C-14), 33.6 (C-10), 
36.6 (C-9), 66.7 (C-6), 70.9 (C-5), 193.3 (C-8). ESI+-MS: m/z 298.3 
[M+H]+ (calcd for C16H28NO4, 298.2).
Citreorosein (21): yellow powder. UV (lmax nm): 221, 287. 1H NMR 
(400 MHz, TMS, DMSO-d6): d (ppm); 4.60 (2H, s, H2-11), 6.56 (1H, 
d, J=2.4 Hz, H-2), 7.09 (1H, d, J=2.4 Hz, H-4), 7.23 (1H, d, J=1.4 
Hz, H-7), 7.62 (d, J=1.4 Hz, 1H, H-5). 13C NMR (100 MHz, TMS, 
DMSO-d6): d (ppm); 189.5 (C-9), 181.3 (C-10), 165.9 (C-1), 164.4 
(C-3), 161.4 (C-8), 152.7 (C-6), 135.0 (C-4a), 132.8 (C-10a), 120.7 (C-
7), 117.0 (C-5), 114.0 (C-8a), 108.9 (C-9a), 108.7 (C-4), 107.8 (C-2), 
61.9 (C-11). ESI+-MS: m/z 287.1 [M+H]+ (calcd for C15H11O6, 287.1).
Quinolactacin C (22): white powder. UV (lmax nm): 218, 250, 
316. 1H NMR and 13C NMR see ref. 27. ESI+-MS: m/z 287.0 [M+H]+ 
(calcd for C16H19N2O3, 287.1).
5-Methylmellein (23): white crystal. UV (lmax nm): 248, 322. 1H 
NMR (500 MHz, TMS, MeOH-d4): d (ppm); 1.51 (3H, d, J=6.31 Hz, 
H3-3’), 2.21 (3H, s, H3-5’), 2.72 (1H, dd, J=16.9, 11.5 Hz, H-4A), 
3.06 (1H, dd, J=16.9, 3.6 Hz, H-4B), 4.70 (1H, m, H-3), 6.76 (1H, d, 
J=7.1 Hz, H-6), 7.34 (1H, d, J=7.1 Hz, H-7).13C NMR (125 MHz, 
TMS, MeOH-d4): d (ppm); 18.3 (C-3’), 21.1 (C-5’), 32.6 (C-4), 77.2 
(C-3), 109.1 (C-9), 116.3 (C-5), 126.7 (C-7), 139.0 (C-6), 139.1 (C-
10), 161.6 (C-8), 172.0 (C-1). ESI+-MS: m/z 193.2 [M+H]+ (calcd 
for C11H13O3, 193.1). [α]D25 –81 (c 1.24, MeOH). 
5 ,7 -D ich lo ro -3 -me thy l -6 -me thoxy -8 -hydroxy -3 ,4 -
dihydroisocoumarin (24): white crystal. UV (lmax nm): 218, 254, 
322. 1H NMR (500 MHz, TMS, DMSO-d6): d (ppm); 1.40 (3H, d, 
J=6.34 Hz, H3-3’), 2.76 (1H, dd, J=16.9, 11.6 Hz, H-4A), 3.14 (1H, 
dd, J=16.8, 3.4 Hz, H-4B), 4.57 (1H, m, H-3), 3.82 (3H, s, H3-6’). 
13C NMR (125 MHz, TMS, DMSO-d6): d (ppm); 20.9 (C-3’), 32.8 
(C-4), 61.3 (C-6’), 72.8 (C-3), 111.3 (C-9), 115.1 (C-7), 115.9 (C-5), 
138.6 (C-10), 154.3 (C-8), 157.3 (C-6), 160.4 (C-1). ESI+-MS: m/z 
275.1 [M+H]+ (calcd for C11H10Cl2O4, 275.9).
(+)-Abscisic acid (25): amorphous solid. UV (lmax nm): 261. 1H 
NMR (500 MHz, TMS, MeOH-d4): d (ppm);1.02 (3H, s, H3-7’), 1.06 
(3H, s, H3-8’), 1.93 (3H, s, H3-9’), 2.03 (3H, s, H3-6), 2.18 (1H, d, 
J=22.5 Hz, H-5’A), 2.53 (1H, d, J=22.5 Hz, H-5’B), 5.74 (1H, s, H-2), 
5.92 (1H, s, H-3’), 6.23 (1H, d, J=20.0 Hz, H-5), 7.76 (1H, d, J=20.0 
Hz, H-4).13C NMR (125 MHz, TMS, MeOH-d4): d (ppm);18.19 (C-
9’), 19.8 (C-6), 22.1 (C-7’), 23.2 (C-8’), 41.4 (C-6’), 49.2 (C-5), 79.2 
(C-1’), 118.4 (C-2), 126.14 (C-3’), 128.0 (C-4), 136.4 (C-5), 149.4 
(C-2’), 165.1 (C-3), 168.2 (C-1), 199.6 (C-4’).ESI+-MS: m/z 287.3 
[M+Na]+ (calcd for C15H20O4Na, 287.1). [α]D25 + 87 (c 2.0, MeOH).
4-hydroxy-3-prenyl-benzoic acid (26): amorphous solid. UV 
(lmax nm): 259. 1H NMR (600 MHz, TMS, MeOH-d4): d (ppm); 1.72 
(3H, br s, H3-11), 1.75 (3H, d, J=1.3 Hz, H3-12), 3.30 (1H, d, J=7.7 
Hz, H-8), 6.77 (1H, d, J=8.4 Hz, H-5), 5.32 (1H, tseptet, J=7.7, 1.3 
Hz, H-9), 7.69 (1H, dd, J=8.4, 2.2 Hz, H-6), 7.74 (1H, d, J=2.2 Hz, 
H-2). 13C NMR (150 MHz, TMS, MeOH-d4): d (ppm); 17.9 (C-12), 
26.0 (C-11), 29.1 (C-8), 115.2 (C-1, C-5), 123.4 (C-9), 129.2 (C-3), 
130.4 (C-6), 132.5 (C-2), 133.6 (C-10), 160.8 (C-4), 171.1 (C-7). 
ESI+-MS: m/z 207.2 [M+H]+ (calcd for C12H15O3, 207.1).
Anofinic acid (27): amorphous solid. UV (lmax nm): 239. 1H NMR 
(600 MHz, TMS, MeOH-d4): d (ppm); 1.43 (6H, s, H3-9, H3-10), 
5.70 (1H, d, J=9.9 Hz, H-3), 6.41 (1H, d, J=9.9 Hz, H-4), 6.69 (1H, d, 
J=8.7 Hz, H-8), 7.64 (1H, br s, H-5), 7.74 (1H, br d, J=8.7 Hz, H-7). 
ESI+-MS: m/z 205.3 [M+H]+ (calcd for C12 H13O3, 205.1). 
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2,3-Dihydro-6,7-dihydroxy-2,2-dimethylchromen-4-one (28): 
amorphous solid. UV (lmax nm): 240, 279, 347. 1H NMR (600 MHz, 
TMS, MeOH-d4): d (ppm); 1.40 (6H, s, H3-9, H3-10), 2.61 (2H, s, 
H2-3), 6.28 (1H, s, H-8), 7.13 (1H, s, H-5). 13C NMR (150 MHz, 
TMS, MeOH-d4): d (ppm); 26.8 (C-9, C-10), 49.3 (C-3), 80.1 (C-2), 
104.6 (C-8), 111.1 (C-5), 113.2 (C-4a), 141.7 (C-6), 156.4 (C-8a), 
157.6 (C-7), 193.8 (C-4). ESI+-HRMS: m/z 209.08167 [M+H]+ (calcd 
for C11H13O4, 209.08138). 
Harzianopyridone (29): amorphous solid. UV (lmax nm): 203, 
237, 269, 333. 1H NMR (500 MHz, TMS, DMSO-d6): d (ppm); 1.01 
(3H, d, J=8.5 Hz, H3-9), 1.56 (3H, d, J=6.1 Hz, H3-13), 1.94 (1H, 
dt, J=14.3, 8.3 Hz, H-10A), 2.35 (1H, dt, J=14.3, 8.3 Hz, H-10B), 3.57 
(3H, s, H3-15), 3.87 (3H, s, H3-14), 3.92 (1H, sextet, J=8.5 Hz, H-8), 
5.33 (2H, m, H1-11, H1-12). 13C NMR (125 MHz, TMS, DMSO-d6): 
d (ppm); 16.9 (C-9), 18.2 (C-13), 36.3 (C-10), 43.2 (C-8), 54.6 (C-15), 
60.4 (C-14), 100.1 (C-3), 121.0 (C-5), 126.7 (C-12), 129.3 (C-11), 
158.9 (C-6), 161.6 (C-2), 172.0 (C-4), 209.0 (C-7). ESI+-MS: m/z 
282.2 [M+H]+ (calcd for C14H20NO5, 282.1).
Pyrenocine A (30): amorphous solid. UV (lmax nm): 228, 274. 1H 
NMR and 13C NMR see refs. 14 and 35. ESI+-MS: m/z 209.0 [M+H]+ 
(calcd for C11H12O4, 209.1).
Pyrenocine B (31): amorphous solid. UV (lmax nm): 262. 1H NMR 
and 13C NMR see refs. 14 and 35. ESI+-MS: m/z 227.0 [M+H]+ (calcd 
for C11H14O5, 227.1).
Conocenol B (32): colorless oil. UV (lmax nm): 236.0. 1H NMR 
(400 MHz, TMS, DMSO-d6,): d (ppm); 2.48 (3H, m), 1.75 (4H, m), 
1.60 (4H, m), 3.73 (5H, d, J=11.0), 1.70 (6H, m), 2.93 (7H, br t, 
J=8.6 Hz), 1.37 (8H, m), 2.16 (10H, dd, J=1.6, 1.6, 14.48 Hz), 
1.80 (10H, br d, J=13.3 Hz), 3.90 (11H, m), 3.53 (12H, d, J=6.0 Hz), 
0.85 (13H, d, J= 6.8 Hz), 1.02 (14H, s), 0.79 (15H, s). ESI+-MS: m/z 
277 [M+Na]+ (calcd for C15H26O3Na, 277.1779 ). [α]D14.7 +84.4 (c 
0.15, MeOH).
Antiviral assays
Virus and cell lines: Cell lines were propagated in monolayer 
cultures using a minimal essential medium (MEM) with Earle’s salts 
supplemented with 10% fetal bovine serum (FBS). The cells were 
inoculated at 1:2 to 1:10 dilutions. When a virus was used with the 
cells, it was necessary to use medium without FBS.37
Cell cytotoxic effect: Cell suspensions (100 µL per well) were 
seeded into 96-well culture plates at a density of 1 x 105 cells/mL. 
The microtiter plates containing the cells were pre-incubated for 24 
h at 37 °C to allow for stabilization prior to the addition of 100 µL 
aliquots of selected compounds at four concentrations: 0.25, 2.5, 25, 
and 250 µg mL-1. The maximum nontoxic concentration (MNTC) 
was determined microscopically by observing the morphological 
changes of the cells at 24, 48 and 72 hours of incubation. After 72 h, 
a (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 
(MTT) assay was performed in order to evaluate the cytotoxic activity 
of the compounds.37
Titration of viruses: Cells were seeded in 96-well culture plates 
at a density of 1 x 105 cells/mL and incubated at 37 ºC for 24 h in a 
humidified atmosphere containing CO2. Serial dilutions of the virus 
stocks were prepared and used to infect the cells. After an additional 
incubation of 1 to 2 days, the cytopathic effect was recorded. The 
50% infective doses in tissue culture (TCID50µL) was calculated as 
previously described.37
Antiviral activity: Determination of the antiviral activity was 
based on cytopathic effect. All experiments were performed in trip-
licate. Briefly, cells were seeded in 96-well culture plates and, after 
24 h of incubation, the medium was replaced with 100 µL Dulbecco’s 
Modified Eagle Medium (DMEM) containing the selected compounds 
at the MNTC. Then, 50 µL logarithmic dilutions of viruses were 
added in quadruplicate and incubated for 2 to 5 days, depending 
on the virus. Controls were untreated infected (virus titer), treated 
noninfected (control), and untreated noninfected. The viral titers were 
determined by the 50% infective doses in tissue culture (TCID50µL). 
The antiviral activity was determined as the logarithm reduction factor 
(log10) of the viral titer compared to the untreated infected controls. 
The values are expressed as titer (TCID50µL) and inhibition percentage 
(IP). The inhibition percentage was calculated using the formula 
(IP) = (1 – T/C) x 100, where T is the antilog of the sample-treated 
viral titers and C is the antilog of the control (without sample treat-
ment with pure compounds) viral titers. The IP was considered to be 
positive if greater than or equal to 98%.
The antiviral activity was initially evaluated with a single dose at 
the MNTC against different viral concentrations. Compounds were 
considered positively active when there was a 1.5 log decrease in the 
viral titer. To confirm the antiviral activity, a concentration response 
curve with different concentrations of the selected compounds in 
the presence of 100 TCID50/mL was determined by the MTT assay, 
in order to establish the 50% antiviral concentration (EC50). Briefly, 
5 mg mL-1 of the MTT solution in PBS were added to 96-well culture 
plates at 20 µl/well at each time point. Following a 4 h incubation, 
100 µL of dimethylsulfoxide (DMSO) were added to each well and 
mixed thoroughly to dissolve the dark-blue formazan crystals. Plates 
were read on an ELISA reader (Molecular Devices SpectraMax Plus) 
at a wavelength of 540 nm.37
Data analysis: The 50% cytotoxic (CC50) and 50% inhibition 
(IC50) concentrations were calculated from concentration-effect cur-
ves (data not shown). The results were obtained from triplicate assays 
with at least five different concentrations for each tested compound. 
The percentage of cytotoxicity was calculated as [(A – B)/A] x 100, 
where A and B were the optical density measured at lmax = 540 nm 
(OD540) of the untreated and treated cells, respectively. The percenta-
ges of protection were calculated as [(A − B) × 100/(C − B)], where 
A, B and C indicate the absorbance of compounds, virus, and cell 
controls, respectively. Each EC50 value was defined as the effective 
concentration that reduced the absorbance of the infected cells to 
50% compared to the cell and virus controls. The therapeutic index 
(i.e., selective index) was defined as CC50/EC50.37
Potential stage in the viral infection cycle: Cells and viruses were 
incubated with compounds 29 and 30, separately, at different stages 
during the viral infection cycle to establish the mode of antiviral 
action. Cells were either pretreated with the compounds before viral 
infection, the viruses were incubated with the compounds before 
cell infection, or the cells were infected with the virus and incubated 
together before the addition of the compounds. The samples were 
used at the maximum noncytotoxic concentration and maintained 
during all experiment.37
Viral inactivation: To determine whether compounds inactivate 
extracellular virus, equal volumes (100 µL) of 10-fold serially diluted 
virus suspension and the MNTC were mixed and incubated for 1 h at 
37 °C. Each mixture was then added to the cell monolayer, and the 
infectious titers were compared to the controls.37
Statistical analysis: The results are expressed as the mean ± s.e.m. 
The selectivity index (SI) is the ratio of CC50 to EC50. The significantly 
different effects of compounds on the inhibition of virus replication 
were compared to the control group using Student’s t-test, with p≤0.05 
indicating a significant result.37
RESULTS AND DISCUSSION
The isolation of new, biologically active fungal metabolites 
is a major challenge, considering the very large number of fungal 
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metabolites isolated so far.5 Therefore, a good strategy to access 
rapid identification of fungal metabolites is mandatory when high-
-throughput, high resolution, and sensitive instrumentation for dere-
plication purposes is unavailable.
The approach herein presented was based on easily available 
and low cost spectroscopic identification techniques: UV spectra, 
low-resolution mass spectrometry and 1H MNR data. Strains were 
grown in media previously selected14 in order to produce an adequate 
amount of material for the isolation of secondary metabolite enriched 
fractions and/or pure compounds. Isolation was performed by several 
chromatographic steps, including gel-permeation, reversed-phase 
and normal-phase chromatography. Analysis of fractions by HPLC-
UV-MS and in bioassays provided key results to pursue the isolation 
of pure compounds. UV maxima were recorded together with m/z 
values observed for [M+H]+, [M-H]- and [M+Na]+ ions, which were 
often detected. Data obtained were enough to provide sufficient 
information for the identification of most of the metabolites isolated 
as pure chemical entities. This approach is summarized in Scheme 1.
One of the difficulties in querying databases such as the 
Dictionary of Natural Products and MarinLit is the return of a very 
large number of results if the molecular formula is not known by 
HRMS analysis. Such outcome makes the identification process 
laborious and time consuming.
The use of 1H NMR and, when necessary, 13C NMR analysis 
provided additional information when the structural information of 
the metabolites detected in the HPLC-UV-MS screening process 
did not have unique UV absorptions that gave a single match or few 
matches during identification. Rapid identification after the purifi-
cation process instead of dereplication during the analysis of crude 
extracts is suitable when: a) there are inherent difficulties in applying 
dereplication to complex mixtures (e.g., instrumentation limitation or 
limited access to databases); b) the identification of pure metabolites 
is required for the construction of an “in-house” database, and; c) the 
isolated compounds display relevant and potent biological activity.
An example that illustrates the effectiveness of the rapid 
identification approach is the identification of sydowic acid (7). 
This metabolite was isolated from the culture medium of the 
marine-derived strain A. sydowii DRG1M2. It has a molecular 
weight of 264 Da that matches other 58 fungal metabolites in the 
DNP database (Table 2). The identification of (7) was possible by 
analysis of LRMS and UV spectra together with analysis of its 1H 
NMR spectrum, which showed three methyl signals at d 0.97 (s), 
d 0.98 (s), and d 1.50 (s), one trisubstituted benzene moiety with 
1H signals at d 7.28 (d, 1.7 Hz), d 7.33 (dd, 8.0 and 1.7 Hz), d 7.38 
(d, 8.0 Hz), and a carboxylic acid 1H at d 9.98 (s). Comparison of 
sydowic acid (7) 1H NMR data with the structures of compounds 
with the same molecular weight and similar UV absorption obtained 
in the DNP enabled its rapid identification,16 with no need for further 
NMR analyses. This approach defrayed the costs of time-consuming 
NMR experiments and provided rapid access to the structures of 
an extensive number of known fungal metabolites, many of which 
have been isolated several decades ago, when bioassays to evaluate 
such metabolites were still very limited.
Of the twenty-six compounds herein reported, the structures 
of (8) and (28) have not been previously reported in the literature. 
Compound (8) was identified as the opposite enantiomer of (+)-5,7-di-
hydroxy-2-[1-(4-methoxy-6-oxo-6H-pyran-2-yl)-2-phenylethylami-
no]-[1,4]naphthoquinone.17 It was isolated as a red amorphous solid 
and presented a [M+H]+ ion at m/z 434.0. Analysis of its 1H NMR 
spectrum indicated signals characteristic of a monosubstituted ben-
zene ring at d 7.30 (m), d 7.28 (m), and d 7.23 (m). Two hydrogens 
observed at d 6.96 (d, 2.3 Hz) and d 6.51 (d, 2.4 Hz) were assigned 
to a tetrasubstituted benzene moiety. Hydrogens characteristic of a 
pyrone group at d 5.98 (d, 2.3 Hz) and d 5.45 (d, 2.3 Hz) were de-
tected, along with a proton at d 5.59 (s) attached to a sp2 carbon, and 
two singlets at d 12.91 (s) and at d 3.77 (s) assigned to a hydroxyl and 
methoxyl groups, respectively. Finally, two diastereotopic hydrogens 
were observed at d 3.31 (dd, 13.9; 6.0 Hz) and d 6.21 (dd, 13.9; 8.2 
Hz). Analysis of its 13C NMR spectrum confirmed the presence of 
a monosubstituted benzene ring at d 132.1, 129.2 (2C), 128.6 (2C) 
and 127.1, the tetrasubstituted aromatic ring at d 163.4, 161.0, 136.3, 
108.9, 108.8, 107.9, the pyrone ring at d 170.7, 163.3, 163.2, 101.2, 
88.3, and a methoxyl group at d 56.2. Two additional sp2 carbon 
signals were observed at d 147.5, 100.4, a heteroatom-substituted 
Scheme 1. Secondary metabolites dereplication process and rapid structural identification
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carbon at d 55.2, two conjugated carbonyl groups d 188.4 and at 
d 180.7, and a methylene at d 38.2.17
For compound (28), a query to the Dictionary of Natural Products 
database showed 68 additional fungal compounds with the same UV 
spectrum (lmax 240, 279 and 347 nm) and molecular weight (m/z 
209.1 for the [M+H]+ ion). Analysis of the 1H, 13C and HSQC NMR 
spectra indicated the presence of a 1,2,4,5-tetrasubstituted benzene 
ring with 1H signals at d 7.13 (s, CH-5) and d 6.28 (s, CH-8). Two 
methyl groups represented by overlapping singlets at d 1.40 (s, H3C-9 
and H3C-10), one methylene group at d 2.61 (s, CH2-3), one carbonyl 
group at d 193.8 (C-4), as well as the presence of five quaternary 
carbons, including two hydroxylated aromatic carbons at d 157.6 (C-
7) and 141.7 (C-6) and one oxymethine group at d 80.1 (C-2), were 
also observed. In the HMBC spectrum of (28), correlations from the 
methylene group at d 2.61 (s) to C-2 (dC 80.1), C-9/C-10 (dC 26.8), 
C-4a (dC 113.2) and C-4 (dC 193.8), confirmed the structure and 
position of the pyranone ring in the molecule. HMBC correlations 
from CH-5 at d 7.13 (s) to C-4a (dC 113.2) and C-8 (dC 104.6), and 
from CH-8 at d 6.28 (s) to C-4a (dC 113.2) confirmed the substitu-
tion pattern of the 1,2,4,5-tetrasubstituted benzene ring. Compound 
(28) was identified as 6,7-dihydroxy-2,2-dimethyl-4-chromanone, 
first synthesized in 1937.38 Related compounds displayed antioxi-
dant activity and are used as inhibitors of self-oxidation of various 
organic substrates such as plastics, lubricants and rubber products 
often exposed to air during manufacturing processes.38,39 Production 
of (28) by Cochliobolus spp. is its first report from a natural source.
Selected compounds were evaluated in antiviral assays. 
Compounds 8, 18, 21, harzianopyridone (29) and pyrenocine A (30) 
displayed moderate to strong antiviral activity (Table 3). Compound 
(18) also showed moderate activity against strains of hepatitis C virus 
at a concentration of 2.5 µg mL-1. 
In order to identify the stage of viral replication on which 
compounds (29) and (30) were active, three different treatments 
were performed. The first treatment consisted of infecting cells 
with viruses and incubating them for 1 h, followed by the addition 
of the compounds. The second treatment consisted of incubating 
the viruses with the compounds, in order to observe virus inacti-
vation during the viral replication phase. Finally, the addition of 
compounds to cells prior to viral infection was performed in order 
to evaluate any effect on viral adsorption. Harzianopyridone (29) 
was active against HSV-1 during the viral inactivation phase (99% 
inhibition), with an EC50 of 0.2 µg mL-1, low toxicity (34 µg mL-1) 
and high selectivity against HSV-1. Pyrenocine A (30) presented 
90% inhibition of AMPV growth during the viral replication 
phase, with an EC50 of 63.27 µg mL-1, as well as 90% inhibition 
of HSV-1 during the viral adsorption phase, with an EC50 of 4.2 
µg mL-1. Pyrenocine A also displayed both cytotoxic activity (~ 3 to 
5 µg mL-1) and low selectivity. Both (29) and (30) displayed antiviral 
activity against HSV-1 KOS (acyclovir resistant HSV-1) virus strain 
(data not shown). Such result is particularly interesting, considering 
that the best drug for the systemic treatment of HSV-1 infection 
is acyclovir, which inhibits viral replication through competitive 
inhibition of the viral DNA polymerase and chain termination of 
viral DNA strains. HSV-1 resistance to acyclovir can result from 
mutations in either the viral TK gene or the viral DNA polymerase 
gene. This resistance is developed both in vitro and in vivo, and it 
Table 1. Secondary metabolites identified by HPLC-UV-MS and 1H NMR analysis
Compounds Filamentous fungi (strain) Molecular formula UV (λmax nm) MS data (m/z)
Sydowic acid (7) A. sydowii (DRG1M2) C24H20NO7 212, 244, 299 247 [M-H2O]+
Naphthoquinoneimine (8) Aspergillus sp. (DLM38) C32H27O10 207, 270, 334 434.0 [M+H]+
Aurosperone A (9) Aspergillus sp. (DLM38) C32H26O10 228, 258, 277 571.1 [M+H]+
Pyranonigrin C (10) Aspergillus sp. (DLM38) C22H22N2O12 231, 290, 329 254.4 [M+H]+
Aurosperone C (11) Aspergillus sp. (DLM38) C31 H29O12 233, 282, 334 593.1 [M+H]+
Pyrophen (12) Aspergillus sp. (DLM38) C16H17NO4 265 323.2 [M+Cl]-
Leucomelone (13) Aspergillus sp. (DLM38) C18H11O7 265 339.2 [M-H]-
Atromentin (14) Aspergillus sp. (DLM38) C18H11O6 266 323.2 [M-H]-
Pyranonigrin B (15) Aspergillus sp. (DLM38) C22H22N2O12 233, 291, 371 254.1 [M+H]+
Penicitrinone A (16) P. glabrum (DLM218) C23H23O5 283, 307, 383 381.2 [M+H]+
Pinselin (17) P. glabrum (DLM218) C16H11O6 235, 263, 295, 384 323.1 [M+Na]+
Emodin (18) P. glabrum (DLM218) and  
P. citrinum (DLM212)
C15H11O5 221, 266, 287 271.2 [M+H]+
Quinolactacin B (19) P. citrinum (DLM212) C15H16N2O2 213, 256, 315 257.2 [M+H]+
Penicillenol A (20) P. citrinum (DLM212) C16H27NO4 224, 283 298.3 [M+H]+
Citreorosein (21) P. citrinum (DLM212) C15H10O6 221, 287 287.1 [M+H]+
Quinolactacin C (22) P. citrinum (DLM212) C16H18N2O3 218, 250, 316 287.0 [M+H]+
5-methylmellein (23) Roussoella sp. (DLM33) C11H12O3 248, 322 193.2 [M+H]+
5,7-Dichloro-3-methyl-6-methoxy-8-hydroxy-3,4-dihy-
droisocoumarin (24)
Roussoella sp. (DLM33) C12H15O3 259 207.2 [M+H]+
(+)-abscisic acid (25) Cochliobolus sp. (F56) C15H20O4 261 287.3 [M+Na]+
4-hydroxy-3-prenyl-benzoic acid (26) Cochliobolus sp. (F56) C12H14O3 259 207.2 [M+H]+
Anofinic acid (27). Cochliobolus sp. (F56) C12 H12O3 239 205.3 [M+H]+
6,7-dihydroxy-2,2-dimethyl-4-chromanone (28) Cochliobolus sp. (F56) C11H12O4 240, 279, 347 209.1 [M+H]+
Harzianopyridone (29) Trichoderma sp. (F254) C14H19NO5 203, 237, 269, 333 282.2 [M+H]+
Pyrenocine A (30) P. paxilli (Ma(G)K) C11H12O4 228, 274 209.0 [M+H]+
Pyrenocine B (31) P. paxilli (Ma(G)K) C11H14O5 262 272.0 [M+H]+
Conocenol B (32) Unidentified (P1AF2F3) C15H26O3 236 277.2 [M+Na]+
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is very significant in immunocompromised patients.10,40 Therefore, 
new, potent, and selective antiviral agents are necessary to provide 
alternative HSV-1 treatment choices, with (29) and (30) representing 
attractive candidates for development as new antivirals. The structu-
ral relatedness of (29) and (30) suggests that such structure scaffolds 
may be of interest for further synthesis and SAR investigations.
Figure 2. Structures of secondary metabolites rapidly identified by UV, LRMS, 1H NMR and, less frequently, by 13C NMR analyses
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CONCLUSION
A strategy for the rapid identification of purified fungal meta-
bolites by HPLC-UV-MS and 1H NMR analyses and, less often, 
by 13C NMR analysis, enabled the identification of 26 compounds 
produced by different marine-derived and endophytic fungal strains. 
Expensive and time-consuming 13C and two-dimensional NMR 
analyses for identification of known metabolites were avoided. An 
unreported enantiomer of (+)-5,7-dihydroxy-2-[1-(4-methoxy-6-
-oxo-6H-pyran-2-yl)-2-phenylethylamino]-[1,4]naphthoquinone, 
(-)-8, and 6,7-dihydroxy-2,2-dimethyl-4-chromanone (28), are herein 
reported as natural products for the first time. Evaluation in antiviral 
assays indicated that pyrenocine A (30) presents significant antiviral 
activity against HSV-1 in the adsorption phase, and against AMPV in 
the replication phase. Harzianopyridone (29) showed potent antiviral 
activity against HSV-1 during the viral inactivation phase coupled 
with a high selectivity, indicating that, although both compounds 
(29) and (30) present structural relatedness, their subtle structural 
differences have to be considered in order to better understand their 
antiviral mechanism-of-action against HSV-1. Since both pyrenocine 
A and harzianopyridone can be obtained via fungal fermentation14,35,34 
or by synthesis,41,42 these compounds clearly represent structural sca-
ffolds worth of investigation for new antiviral leads in drug discovery.
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